Form 8-K
8-K — Dermata Therapeutics, Inc.
Accession: 0001493152-26-025441
Filed: 2026-05-27
Period: 2026-05-27
CIK: 0001853816
SIC: 2834 (PHARMACEUTICAL PREPARATIONS)
Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item: Submission of Matters to a Vote of Security Holders
Item: Financial Statements and Exhibits
Documents
8-K — form8-k.htm (Primary)
EX-10.1 (ex10-1.htm)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: form8-k.htm · Sequence: 1
false
0001853816
0001853816
2026-05-27
2026-05-27
0001853816
DRMA:CommonStockParValue0.0001PerShareMember
2026-05-27
2026-05-27
0001853816
DRMA:WarrantsExercisableForOneShareOfCommonStockMember
2026-05-27
2026-05-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 27, 2026
Dermata
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
001-40739
86-3218736
(State
or Other Jurisdiction
of
Incorporation)
(Commission
File Number)
(I.R.S.
Employer
Identification
No.)
3525
Del Mar Heights Rd., #322
San
Diego, CA
92130
(Address
of principal executive offices)
(Zip
Code)
(858)
800-2543
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of Each Class:
Trading
Symbol
Name
of Each Exchange on which Registered
Common
Stock, par value $0.0001 per share
DRMA
The
Nasdaq Capital Market
Warrants,
exercisable for one share of Common Stock
DRMAW
The
Nasdaq Capital Market
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR§230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
May 27, 2026, Dermata Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the
“Annual Meeting”). At the Annual Meeting, shareholders approved an amendment to the Company’s 2021 Omnibus
Equity Incentive Plan (the “2021 Plan”) to increase the number of shares available for issuance thereunder
to 402,214 shares (the “Plan Amendment”).
The
foregoing description of the Plan Amendment does not purport to be complete and is qualified in its entirety by reference to the full
text of the Plan Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.
Item
5.07 Submission of Matters to a Vote of Security Holders.
At
the Annual Meeting, 2,374,471 common
shares, or approximately 59% of
the outstanding shares of common stock entitled to vote, were represented by proxy or in person. The matters voted on at the Annual Meeting
were: (1) the election of three Class II directors; (2) the ratification of the appointment of CBIZ CPAs P.C.
as the Company’s independent registered public accounting
firm for the fiscal year ending December 31, 2026 (the “Auditor Proposal”); (3) the approval, for purposes
of complying with Nasdaq Listing Rule 5635(d), of the issuance of shares of the Company’s common stock, par value $0.0001 per share
(“Common Stock”), underlying certain warrants issued by the Company pursuant to that certain Securities Purchase
Agreement, dated as of December 23, 2025, by and among the Company and the investors named on the signatory pages thereto, and the Engagement
Letter, as amended, between the Company and H.C. Wainwright & Co., LLC, dated as of September 10, 2024 (the “Engagement
Letter”), in an amount equal to or in excess of 20% of the Common Stock outstanding immediately prior to the issuance of
such warrants (the “Issuance Proposal”); (4) the approval of the repricing of warrants exercisable for up to
120,734 shares of Common Stock issued by the Company to investors pursuant to certain securities purchase agreements, each dated as of
January 21, 2025, and each as amended on December 23, 2025 (the “Warrant Repricing Proposal”); (5) the approval
of an amendment to the 2021 Plan to increase the maximum aggregate number of shares of Common Stock reserved for issuance under the 2021
Plan to 402,214 shares (the “Plan Amendment Proposal”); and (6) the approval of the adjournment of the Annual
Meeting to the extent there are insufficient votes at the Annual Meeting to approve the Issuance Proposal, the Repricing Proposal and/or
the Plan Amendment Proposal (the “Adjournment Proposal”). The final voting results were as follows:
1.
The stockholders elected David Hale, Steven Mento, Ph.D. and Brittany Bradrick as Class II directors to serve until the 2029 annual meeting
and until their successors have been duly elected and qualified. The votes were cast for this matter as follows:
Nominee
For
Withheld
Broker
Non-Votes
David Hale
1,258,269
47,546
1,068,656
Steven Mento Ph.D.
1,258,871
46,944
1,068,656
Brittany Bradrick
1,262,134
43,681
1,068,656
2.
The Auditor Proposal was approved based upon the following votes:
For
Against
Abstain
2,329,537
43,122
1,812
3.
The Issuance Proposal was approved based upon the following votes:
For
Against
Abstain
Broker
Non-Votes
315,477
22,696
967,642
1,068,656
4.
The Warrant Repricing Proposal was approved based upon the following votes:
For
Against
Abstain
Broker
Non-Votes
439,573
21,203
845,039
1,068,656
5.
The Plan Amendment Proposal was approved based upon the following votes:
For
Against
Abstain
Broker
Non-Votes
1,243,540
47,441
14,834
1,068,656
6.
The Adjournment Proposal was approved based upon the following votes:
For
Against
Abstain
1,269,857
21,137
14,821
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
Exhibit
No.
Description
10.1
Fourth Amendment to the
Dermata Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan.
104
Cover Page Interactive Data File (embedded
within the Inline XBRL document).
Signature
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
DERMATA
THERAPEUTICS, INC.
Dated:
May 27, 2026
By:
/s/
Gerald T. Proehl
Gerald
T. Proehl
Chief
Executive Officer
EX-10.1
EX-10.1
Filename: ex10-1.htm · Sequence: 2
Exhibit 10.1
FOURTH AMENDMENT TO THE
DERMATA THERAPEUTICS, INC.
2021 OMNIBUS EQUITY INCENTIVE
PLAN
This
Fourth Amendment (the “Amendment”) to the Dermata Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (the “Plan”)
of Dermata Therapeutics, Inc. (the “Company”), is made as of March 25, 2026. All capitalized terms used but not defined
in this Amendment shall have the meanings assigned to such terms in the Plan.
WITNESSETH:
WHEREAS,
Section 17.2 of the Plan reserves to the Board of Directors of the Company (the “Board”) the right to amend the Plan
from time to time;
WHEREAS,
the Board desires to increase the number of shares of Common Stock reserved for issuance under the Plan from 153,586 to 402,214 shares,
subject to approval by the Company’s stockholders.
NOW,
THEREFORE, be it effective as of the date of approval by the Company’s stockholders, the Plan is hereby amended as follows:
1. Amendment
to Section 4.1(a). Section 4.1(a) of the Plan is hereby amended and restated in its entirety, to read as follows:
(a) Subject
to adjustment pursuant to Section 4.3 and any other applicable provisions hereof, the maximum aggregate number of shares of Common Stock,
which may be issued under all Awards granted to Participants under the Plan, shall be 402,214 shares; all of which may, but need not,
be issued in respect of Incentive Stock Options.
2. This
Amendment shall be subject to approval by the stockholders of the Company within 12 months after the date this Amendment is adopted. Such
stockholder approval shall be obtained in the manner and to the degree required under applicable laws. Notwithstanding any provision in
the Plan to the contrary, exercise of any Option granted for shares of Common Stock in excess of those remaining available for grant under
the Plan in the absence of such Amendment before the Company has obtained stockholder approval of this Amendment in accordance with this
Section 2 shall be conditioned upon obtaining such stockholder approval of this Amendment in accordance with this Section 2.
3. Except
as set forth herein, the Plan shall remain in full force and effect without modification.
IN WITNESS WHEREOF, the undersigned officer hereby certifies that
the foregoing amendment to the Plan was duly adopted and approved by the Board.
DERMATA THERAPEUTICS, INC.
Dated:
March 25, 2026
By:
/s/
Gerald T. Proehl
Gerald
T. Proehl
Chief
Executive Officer
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 8
v3.26.1
Cover
May 27, 2026
Document Type
8-K
Amendment Flag
false
Document Period End Date
May 27, 2026
Entity File Number
001-40739
Entity Registrant Name
Dermata
Therapeutics, Inc.
Entity Central Index Key
0001853816
Entity Tax Identification Number
86-3218736
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
3525
Del Mar Heights Rd.
Entity Address, Address Line Two
#322
Entity Address, City or Town
San
Diego
Entity Address, State or Province
CA
Entity Address, Postal Zip Code
92130
City Area Code
(858)
Local Phone Number
800-2543
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Entity Emerging Growth Company
true
Elected Not To Use the Extended Transition Period
true
Common Stock, par value $0.0001 per share
Title of 12(b) Security
Common
Stock, par value $0.0001 per share
Trading Symbol
DRMA
Security Exchange Name
NASDAQ
Warrants, exercisable for one share of Common Stock
Title of 12(b) Security
Warrants,
exercisable for one share of Common Stock
Trading Symbol
DRMAW
Security Exchange Name
NASDAQ
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine2
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details
Name:
dei_EntityExTransitionPeriod
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=DRMA_CommonStockParValue0.0001PerShareMember
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=DRMA_WarrantsExercisableForOneShareOfCommonStockMember
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type: